Sanford Markowitz
Corporate Officer/Principal presso Case Western Reserve University School of Medicine
Profilo
Sanford Markowitz was the founder of Rodeo Therapeutics Corp.
which was founded in 2017, where he held the title of Director.
Currently, he is a Professor at Case Western Reserve University School of Medicine since 1988.
Previously, he was a Director at Lucid Diagnostics, Inc. Dr. Markowitz received his undergraduate degree from Harvard University and his doctorate from Yale University.
Posizioni attive di Sanford Markowitz
| Società | Posizione | Inizio |
|---|---|---|
| Case Western Reserve University School of Medicine | Corporate Officer/Principal | 01/01/1988 |
Precedenti posizioni note di Sanford Markowitz
| Società | Posizione | Fine |
|---|---|---|
| LUCID DIAGNOSTICS INC. | Direttore/Membro del Consiglio | - |
Rodeo Therapeutics Corp.
 Rodeo Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Rodeo Therapeutics Corp. engages in the development of drugs. The firm develops novel small molecules therapies for the treatment of inflammatory bowel disease and the promotion of blood cell reconstitution following bone marrow transplant. It focuses on the development of small-molecule therapies that increase tissue levels of prostaglandin PGE2. The company was founded by Stanton Gerson, Sanford Markowitz, and Joseph Ready on May 15, 2017 and is headquartered in Seattle, WA. | Fondatore | - |
Formazione di Sanford Markowitz
| Harvard University | Undergraduate Degree |
| Yale University | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| LUCID DIAGNOSTICS INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Rodeo Therapeutics Corp.
Rodeo Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Rodeo Therapeutics Corp. engages in the development of drugs. The firm develops novel small molecules therapies for the treatment of inflammatory bowel disease and the promotion of blood cell reconstitution following bone marrow transplant. It focuses on the development of small-molecule therapies that increase tissue levels of prostaglandin PGE2. The company was founded by Stanton Gerson, Sanford Markowitz, and Joseph Ready on May 15, 2017 and is headquartered in Seattle, WA. | Health Technology |
- Borsa valori
- Insiders
- Sanford Markowitz
